Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Art Cashin on CNBC- If covid has a resurgence in Asia all bets are off.
He went to explain that in times past there have been "local" melt downs in Europe, the U.S., Asia. But not anything to this extent when there is a truly global instance affecting civilization.
In response to some that believe that masks don't work and remediation doesn't work The problem is that people aren't observing mask use. Plain and simple. So they aren't only jeopardizing themselves, but they're jeopardizing the health of others, as demonstrated by the covid surge in the Midwest and west because of their belief that masks don't matter.
My family had gotten away from using N95's and were using surgical paper masks ( about a 60% protection rate and more if the other persons use it- to virtually 100% protection) but have since ordered KN95 masks and will begin to use them when around others.
Unfortunately this (covid) isn't going away because of the sheer stupidity of others. So we all suffer. Let's all point fingers where they need to be pointed. Let's not make excuses.
Denying over a quarter of a million deaths from covid or calling it deaths' from something else and saying there's no proof of deaths and infections from covid is downright obtuse.
Well, I was looking for the opportunity to sell my losers to take off taxable gains. I guess this could that opportunity.
Added to AAPL at 113
Added to HD at 272
Added to SLV at 22.48
Added to COST at 367
Closed MCFE at 18.25 at cost.
Added to DNB at 25.80
Added to SLV again at 21.70
The biggest toll in my accounts is MA. It's lost thousands and thousands. Now at cost and dropping.
SURPRISE AND FEAR.... RUTHLESS EFFICIENCY AND AN ALMOST FANATICAL DEVOTION TO THE POPE... CARDINAL,THE RACK...
WELCOME TO THE SPANISH INQUISITION... OVERNIGHT MARKETS TANKING AND THE U.S. FUTURES HEADED TOWARD THE THIRD LEVEL OF HELL.
ABBV IS HELPING
Time to withdraw and go swim, for like the next few months.
IT'S GOING TO GET NASTY.
Reopened EQH at 18.50
Yep, a big mistake.
Added to ABBV at 83.40
Added to another lost cause- CSCO- options on this give it the chance to get back to 38.
Added to CSCO at 36.75
The damn things can't go down forever ! I might be wrong about ABBV not going down forever though.
Back to News Results
Benzinga's Top Upgrades, Downgrades For October 23, 2020
10:48 am ET October 23, 2020 (Benzinga) Print
Upgrades
For Mattel Inc (NASDAQ: MAT), DA Davidson upgraded the previous rating of Neutral to the current rating Buy. In the third quarter, Mattel showed an EPS of $0.95, compared to $0.26 from the year-ago quarter. The stock has a 52-week-high of 14.83 and a 52-week-low of 6.53. At the end of the last trading period, Mattel closed at $12.92.
For Spire Inc (NYSE: SR), Credit Suisse upgraded the previous rating of Neutral to the current rating Outperform. Spire earned $0.07 in the third quarter, compared to $0.07 in the year-ago quarter. The current stock performance of Spire shows a 52-week-high of 87.96 and a 52-week-low of 50.58. Moreover, at the end of the last trading period, the closing price was at $58.24.
According to Stephens & Co., the prior rating for Stewart Information Services Corp (NYSE: STC) was changed from Equal-Weight to Overweight. For the third quarter, Stewart Information Servs had an EPS of $2.21, compared to year-ago quarter EPS of $1.28. The current stock performance of Stewart Information Servs shows a 52-week-high of 49.48 and a 52-week-low of 20.26. Moreover, at the end of the last trading period, the closing price was at $42.10.
Susquehanna upgraded the previous rating for StoneCo Ltd (NASDAQ: STNE) from Neutral to Positive. In the second quarter, StoneCo showed an EPS of $0.10, compared to $0.16 from the year-ago quarter. The current stock performance of StoneCo shows a 52-week-high of 60.76 and a 52-week-low of 17.72. Moreover, at the end of the last trading period, the closing price was at $57.88.
Susquehanna upgraded the previous rating for PulteGroup Inc (NYSE: PHM) from Neutral to Positive. In the third quarter, PulteGroup showed an EPS of $1.34, compared to $1.01 from the year-ago quarter. The current stock performance of PulteGroup shows a 52-week-high of 49.7 and a 52-week-low of 17.12. Moreover, at the end of the last trading period, the closing price was at $42.65.
MKM Partners upgraded the previous rating for Motorola Solutions Inc (NYSE: MSI) from Neutral to Buy. In the second quarter, Motorola Solutions showed an EPS of $1.39, compared to $1.69 from the year-ago quarter. The current stock performance of Motorola Solutions shows a 52-week-high of 187.49 and a 52-week-low of 120.77. Moreover, at the end of the last trading period, the closing price was at $168.99.
Benchmark upgraded the previous rating for Seagate Technology PLC (NASDAQ: STX) from Hold to Buy. Seagate Technology earned $0.93 in the first quarter, compared to $1.03 in the year-ago quarter. The stock has a 52-week-high of 64.17 and a 52-week-low of 39.02. At the end of the last trading period, Seagate Technology closed at $51.79.
For TRI Pointe Group Inc (NYSE: TPH), B. Riley FBR upgraded the previous rating of Neutral to the current rating Buy. In the third quarter, TRI Pointe Group showed an EPS of $0.63, compared to $0.44 from the year-ago quarter. The stock has a 52-week-high of 19.59 and a 52-week-low of 5.89. At the end of the last trading period, TRI Pointe Group closed at $16.79.
JMP Securities upgraded the previous rating for Redwood Trust Inc (NYSE: RWT) from Market Perform to Market Outperform. In the second quarter, Redwood Trust showed an EPS of $1.00, compared to $0.39 from the year-ago quarter. At the moment, the stock has a 52-week-high of 18.01 and a 52-week-low of 2.14. Redwood Trust closed at $8.35 at the end of the last trading period.
RBC Capital upgraded the previous rating for PulteGroup Inc (NYSE: PHM) from Sector Perform to Outperform. In the third quarter, PulteGroup showed an EPS of $1.34, compared to $1.01 from the year-ago quarter. The current stock performance of PulteGroup shows a 52-week-high of 49.7 and a 52-week-low of 17.12. Moreover, at the end of the last trading period, the closing price was at $42.65.
According to RBC Capital, the prior rating for Whirlpool Corp (NYSE: WHR) was changed from Underperform to Sector Perform. For the third quarter, Whirlpool had an EPS of $6.91, compared to year-ago quarter EPS of $3.97. The current stock performance of Whirlpool shows a 52-week-high of 207.3 and a 52-week-low of 64.0. Moreover, at the end of the last trading period, the closing price was at $193.77.
According to Piper Sandler, the prior rating for EOG Resources Inc (NYSE: EOG) was changed from Neutral to Overweight. For the second quarter, EOG Resources had an EPS of $0.23, compared to year-ago quarter EPS of $1.31. The current stock performance of EOG Resources shows a 52-week-high of 89.54 and a 52-week-low of 27.0001. Moreover, at the end of the last trading period, the closing price was at $36.92.
Piper Sandler upgraded the previous rating for Pioneer Natural Resources Co (NYSE: PXD) from Neutral to Overweight. For the second quarter, Pioneer Natural Resources had an EPS of $0.32, compared to year-ago quarter EPS of $2.01. The stock has a 52-week-high of 159.01 and a 52-week-low of 48.62. At the end of the last trading period, Pioneer Natural Resources closed at $83.02.
Downgrades
For The Kroger Co (NYSE: KR), Evercore ISI Group downgraded the previous rating of Outperform to the current rating In-Line. For the second quarter, Kroger had an EPS of $0.73, compared to year-ago quarter EPS of $0.44. The current stock performance of Kroger shows a 52-week-high of 37.22 and a 52-week-low of 24.09. Moreover, at the end of the last trading period, the closing price was at $32.64.
Keefe, Bruyette & Woods downgraded the previous rating for Wintrust Financial Corp (NASDAQ: WTFC) from Outperform to Market Perform. Wintrust Financial earned $1.67 in the third quarter, compared to $1.69 in the year-ago quarter. At the moment, the stock has a 52-week-high of 71.95 and a 52-week-low of 22.0215. Wintrust Financial closed at $50.34 at the end of the last trading period.
JP Morgan downgraded the previous rating for TAL Education Group (NYSE: TAL) from Overweight to Neutral. In the second quarter, TAL Education showed an EPS of $0.08, compared to $0.02 from the year-ago quarter. The stock has a 52-week-high of 83.675 and a 52-week-low of 36.12. At the end of the last trading period, TAL Education closed at $66.30.
According to Jefferies, the prior rating for Navistar International Corp (NYSE: NAV) was changed from Buy to Hold. Navistar International earned $0.08 in the third quarter, compared to $1.47 in the year-ago quarter. The stock has a 52-week-high of 45.25 and a 52-week-low of 15.01. At the end of the last trading period, Navistar International closed at $43.12.
For Citrix Systems Inc (NASDAQ: CTXS), Morgan Stanley downgraded the previous rating of Overweight to the current rating Equal-Weight. Citrix Systems earned $1.38 in the third quarter, compared to $1.52 in the year-ago quarter. The current stock performance of Citrix Systems shows a 52-week-high of 173.56 and a 52-week-low of 100.31. Moreover, at the end of the last trading period, the closing price was at $126.65.
Initiations
With a current rating of Buy, Truist Securities initiated coverage on Pfizer Inc (NYSE: PFE). The price target seems to have been set at $42.00 for Pfizer. Pfizer earned $0.78 in the second quarter, compared to $0.80 in the year-ago quarter. At the moment, the stock has a 52-week-high of 40.97 and a 52-week-low of 27.88. Pfizer closed at $37.46 at the end of the last trading period.
Truist Securities initiated coverage on Merck & Co Inc (NYSE: MRK) with a Buy rating. The price target for Merck & Co is set to $96.00. In the second quarter, Merck & Co showed an EPS of $1.37, compared to $1.30 from the year-ago quarter. At the moment, the stock has a 52-week-high of 92.64 and a 52-week-low of 65.25. Merck & Co closed at $79.20 at the end of the last trading period.
Truist Securities initiated coverage on Eli Lilly and Co (NYSE: LLY) with a Buy rating. The price target for Eli Lilly is set to $180.00. Eli Lilly earned $1.89 in the second quarter, compared to $1.50 in the year-ago quarter. At the moment, the stock has a 52-week-high of 170.75 and a 52-week-low of 101.36. Eli Lilly closed at $141.59 at the end of the last trading period.
Truist Securities initiated coverage on Bristol-Myers Squibb Company (NYSE: BMY) with a Hold rating. The price target for Bristol-Myers Squibb is set to $65.00. Bristol-Myers Squibb earned $1.63 in the second quarter, compared to $1.18 in the year-ago quarter. At the moment, the stock has a 52-week-high of 68.34 and a 52-week-low of 45.76. Bristol-Myers Squibb closed at $60.76 at the end of the last trading period.
With a current rating of Buy, Truist Securities initiated coverage on AbbVie Inc (NYSE: ABBV). The price target seems to have been set at $110.00 for AbbVie. AbbVie earned $2.34 in the second quarter, compared to $2.26 in the year-ago quarter. The current stock performance of AbbVie shows a 52-week-high of 101.28 and a 52-week-low of 62.55. Moreover, at the end of the last trading period, the closing price was at $84.30.
With a current rating of Buy, HC Wainwright & Co. initiated coverage on ClearSign Technologies Corp (NASDAQ: CLIR). The price target seems to have been set at $4.00 for ClearSign Technologies. ClearSign Technologies earned $0.05 in the second quarter, compared to $0.09 in the year-ago quarter. The stock has a 52-week-high of 4.11 and a 52-week-low of 0.35. At the end of the last trading period, ClearSign Technologies closed at $2.48.
RBC Capital initiated coverage on WAVE Life Sciences Ltd (NASDAQ: WVE) with a Sector Perform rating. The price target for WAVE Life Sciences is set to $13.00. In the second quarter, WAVE Life Sciences showed an EPS of $1.15, compared to $1.22 from the year-ago quarter. At the moment, the stock has a 52-week-high of 39.98 and a 52-week-low of 6.61. WAVE Life Sciences closed at $8.31 at the end of the last trading period.
With a current rating of Overweight, Cantor Fitzgerald initiated coverage on Stoke Therapeutics Inc (NASDAQ: STOK). The price target seems to have been set at $49.00 for Stoke Therapeutics. Stoke Therapeutics earned $0.39 in the second quarter, compared to $1.54 in the year-ago quarter. The current stock performance of Stoke Therapeutics shows a 52-week-high of 40.7 and a 52-week-low of 15.82. Moreover, at the end of the last trading period, the closing price was at $38.81.
JMP Securities initiated coverage on Shutterstock Inc (NYSE: SSTK) with a Market Outperform rating. The price target for Shutterstock is set to $72.00. For the second quarter, Shutterstock had an EPS of $0.62, compared to year-ago quarter EPS of $0.33. The stock has a 52-week-high of 62.58 and a 52-week-low of 28.76. At the end of the last trading period, Shutterstock closed at $60.33.
With a current rating of Outperform, Oppenheimer initiated coverage on Shake Shack Inc (NYSE: SHAK). The price target seems to have been set at $90.00 for Shake Shack. Shake Shack earned $0.45 in the second quarter, compared to $0.27 in the year-ago quarter. At the moment, the stock has a 52-week-high of 93.0355 and a 52-week-low of 30.01. Shake Shack closed at $72.56 at the end of the last trading period.
With a current rating of Overweight, Cantor Fitzgerald initiated coverage on Cassava Sciences Inc (NASDAQ: SAVA). The price target seems to have been set at $24.00 for Cassava Sciences. Cassava Sciences earned $0.05 in the second quarter, compared to $0.06 in the year-ago quarter. The stock has a 52-week-high of 12.68 and a 52-week-low of 1.05. At the end of the last trading period, Cassava Sciences closed at $8.83.
RBC Capital initiated coverage on uniQure NV (NASDAQ: QURE) with an Outperform rating. The price target for uniQure is set to $61.00. uniQure earned $0.96 in the second quarter, compared to $0.83 in the year-ago quarter. The current stock performance of uniQure shows a 52-week-high of 76.6869 and a 52-week-low of 34.38. Moreover, at the end of the last trading period, the closing price was at $41.26.
With a current rating of Buy, Guggenheim initiated coverage on Nevro Corp (NYSE: NVRO). The price target seems to have been set at $190.00 for Nevro. For the second quarter, Nevro had an EPS of $1.21, compared to year-ago quarter EPS of $0.91. The current stock performance of Nevro shows a 52-week-high of 166.29 and a 52-week-low of 65.05. Moreover, at the end of the last trading period, the closing price was at $162.39.
RBC Capital initiated coverage on MeiraGTx Holdings PLC (NASDAQ: MGTX) with an Outperform rating. The price target for MeiraGTx Hldgs is set to $27.00. MeiraGTx Hldgs earned $0.69 in the second quarter, compared to $0.63 in the year-ago quarter. The current stock performance of MeiraGTx Hldgs shows a 52-week-high of 22.32 and a 52-week-low of 8.82. Moreover, at the end of the last trading period, the closing price was at $13.09.
With a current rating of Buy, Stifel initiated coverage on Hycroft Mining Holding Corp (NASDAQ: HYMC). The price target seems to have been set at $15.00 for Hycroft Mining Holding. The current stock performance of Hycroft Mining Holding shows a 52-week-high of 16.1713 and a 52-week-low of 6.8. Moreover, at the end of the last trading period, the closing price was at $7.75.
Brookline Capital initiated coverage on electroCore Inc (NASDAQ: ECOR) with a Buy rating. The price target for electroCore is set to $5.00. In the second quarter, electroCore showed an EPS of $0.13, compared to $0.41 from the year-ago quarter. At the moment, the stock has a 52-week-high of 3.3 and a 52-week-low of 0.3201. electroCore closed at $1.57 at the end of the last trading period.
Brookline Capital initiated coverage on CTI BioPharma Corp (NASDAQ: CTIC) with a Buy rating. The price target for CTI BioPharma is set to $7.00. In the second quarter, CTI BioPharma showed an EPS of $0.19, compared to $0.19 from the year-ago quarter. The current stock performance of CTI BioPharma shows a 52-week-high of 3.68 and a 52-week-low of 0.62. Moreover, at the end of the last trading period, the closing price was at $3.34.
With a current rating of Sector Perform, RBC Capital initiated coverage on CRISPR Therapeutics AG (NASDAQ: CRSP). The price target seems to have been set at $110.00 for CRISPR Therapeutics. For the second quarter, CRISPR Therapeutics had an EPS of $1.30, compared to year-ago quarter EPS of $1.01. The current stock performance of CRISPR Therapeutics shows a 52-week-high of 111.9 and a 52-week-low of 32.3. Moreover, at the end of the last trading period, the closing price was at $90.16.
Wedbush initiated coverage on BigCommerce Holdings Inc (NASDAQ: BIGC) with a Neutral rating. The price target for BigCommerce Holdings is set to $90.00. Interestingly, in the second quarter, BigCommerce Holdings's EPS was $0.38. The current stock performance of BigCommerce Holdings shows a 52-week-high of 162.5 and a 52-week-low of 63.7716. Moreover, at the end of the last trading period, the closing price was at $89.95.
Guggenheim initiated coverage on Axonics Modulation Technologies Inc (NASDAQ: AXNX) with a Buy rating. The price target for Axonics Modulation Tech is set to $77.00. For the second quarter, Axonics Modulation Tech had an EPS of $0.54, compared to year-ago quarter EPS of $0.68. The stock has a 52-week-high of 52.1 and a 52-week-low of 15.25. At the end of the last trading period, Axonics Modulation Tech closed at $48.52.
Guggenheim initiated coverage on Axogen Inc (NASDAQ: AXGN) with a Buy rating. The price target for Axogen is set to $24.00. Axogen earned $0.15 in the second quarter, compared to $0.10 in the year-ago quarter. The stock has a 52-week-high of 18.84 and a 52-week-low of 7.16. At the end of the last trading period, Axogen closed at $13.35.
With a current rating of Outperform, RBC Capital initiated coverage on Allogene Therapeutics Inc (NASDAQ: ALLO). The price target seems to have been set at $55.00 for Allogene Therapeutics. In the second quarter, Allogene Therapeutics showed an EPS of $0.53, compared to $0.41 from the year-ago quarter. The current stock performance of Allogene Therapeutics shows a 52-week-high of 55.0 and a 52-week-low of 17.43. Moreover, at the end of the last trading period, the closing price was at $35.34.
RBC Capital initiated coverage on HealthEquity Inc (NASDAQ: HQY) with an Outperform rating. The price target for HealthEquity is set to $67.00. In the second quarter, HealthEquity showed an EPS of $0.42, compared to $0.45 from the year-ago quarter. At the moment, the stock has a 52-week-high of 88.78 and a 52-week-low of 34.4. HealthEquity closed at $55.14 at the end of the last trading period.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Opened MSFT at 213.65....and of course, its gone down some.
PLTR is a new issue of a going company. I'm a long term investor in PLTR.
Back to News Results
Palantir Stock Just Got a Bunch of New Ratings. What Wall Street Is Saying. -- Barrons.com
3:05 pm ET October 26, 2020 (Dow Jones) Print
By Eric J. Savitz
Palantir is a polarizing company. The big data analytics software provider has both huge fans who admire its ability to dig out insights in vast data sets, and detractors who dislike the company's strong ties to the U.S. government, which provides about half of the company's business.
Software analysts are split on the company as well, and politics is part of the equation. The stock (ticker: PLTR) trades at a much lower multiple of sales than other fast-growth enterprise software companies, and bulls see a bargain. But others are wary of the company's high reliance on government contracts and the possibility that a change in the White House in next week's election might not play in Palantir's favor, given Thiel's previous association with President Donald Trump.
At least a half dozen analysts picked up coverage of the stock on Monday following Palantir's direct stock listing on the New York Stock Exchange in late September. The stock opened for trading at $10 and has since traded modestly lower. On Monday, the stock was up 4.3%, to $9.90.
Morgan Stanley analyst Keith Weiss picked up coverage with an Overweight rating and $13 target price. "Unlocking the value within disparate data sets opens up a large and inflecting market opportunity, while rapid margin improvements highlight the shift towards software platforms and away from consulting engagements, creating an attractive risk/reward at Palantir's discounted valuation," the analyst writes in a research note.
Weiss asserts that the stock trades at about a 35% discount to peer software companies on a multiple of sales basis, and a 55% discount on a growth-adjusted basis. "This discount reflects investor concerns on the 'opinionated' nature of the platform limiting the potential customer opportunity and long-term growth prospects, as well as concerns Palantir is fundamentally more 'consulting-like 'with limited long-term margin potential," he writes. "Our work, however, suggests plenty of room to sustain top-line momentum, particularly in the government segment while success with commercial enterprises could represent upside to our estimates."
Jefferies analyst Brent Thill likewise starts coverage with a Buy rating and $13 target. "Palantir's data platform is highly unique and often deployed for mission-critical use cases that no other vendor can address, " he writes. "[The company's] $1 billion+ scale is impressive but the primary investor concern is customer concentration (the top 20 generate $25 million in business on average). More repeatable new logo adds can broaden its reach to support 30%+ growth with growing profitability." Like Weiss, he notes that the stock trades at a deep discount to peer software companies.
Other analysts are more cautious.
Credit Suisse analyst Brad Zelnick sets a Neutral rating and $11 target. "The company's technology and differentiation is uniquely defined by its use cases -- integrating cross agency intelligence data to help uncover and catch terrorists, saving soldiers' lives by identifying likely areas IEDs may be planted, as well as many high-value applications across many industries in the private sector," he writes. "Lack of disclosures around historical trends ... limit one's ability to gain confidence around the sustainability of growth and profitability. We believe lack of disclosure are due in part to the lumpy nature of new business and outsized contribution from large new deals."
Goldman Sachs analyst Christopher Merwin likewise launches with a Neutral rating and $10 target price. "Palantir offers a uniquely powerful data operating system to government and commercial clients," he writes. "We believe the platform is particularly valuable for customers looking to utilize massive amounts of structured and unstructured data to derive actionable and real-time insights... But with just 125 customers today, lumpy deals, and limited visibility into future pipeline conversion, we believe Palantir will likely trade at a discounted multiple relative to comparable growth peers."
Citi's Tyler Radke is similarly cautious, starting the stock with a Neutral rating and $10 target. "We see potential for significant customer wallet share growth as Palantir captures spend across multiple data / analytics categories and automates existing IT services / integration work," he writes. "At the same time we are worried about the scalability and market fit in a rapidly evolving competitive environment. Recent leading indicators around customer growth and hiring gives us further pause here. Finally, we see a number of unusual company-specific risks including near-term political risk (with projects that could be deemed controversial), insider selling and complex ownership structure."
Write to Eric J. Savitz at eric.savitz@barrons.com
(END) Dow Jones Newswires
October 26, 2020 15:05 ET (19:05 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Thank you Nick, not quite the atta boy I was hoping for, but close.
Reopened BX again at 52, from a recent close of 54.
I can't wait till before year end to clean out the trading account of doggies to (in a minor way) offset some incredible ( ly expensive April 2021 tax payments ) taxable gains this year.
Afterward the portfolio will look really good. I might even have some cash left in April to buy stock with after the IRS finishes with me.
I don't follow the rest, but T isn't something I'd recommend unless positioned at a cost basis of 26 or less. Yes it has a good dividend and generates a ton of money, but it's asset value can't get out of its own way. T's stock price continues to flounder. Given the mostly negative to stagnant corporate reports and meandering ways management has handled strategy, hence share price value. I wouldn't touch the stock over 26 per share.
Higher than 28 I'd actually consider a short.
Added to AB at 30.30
Yeah, and I think I'll pass on adding to RTX right now. RTX at 60.23 was another of many mistakes made this morning. Didn't have my Wheaties today.
I inaccurately stated reopening price on ETSY- actual price was 144.35 in one account, and unfortunately in another at 147, which I'm really going to regret. Will add at 125. Really don't know what I was thinking. Time to go for a swim. Get out of this morass.
Trimmed COST at 370 from a cost basis of 339
Added to HD at 278
Reopened RTX with a terrible tasting nibble at 60.23. Will add below 58.50, CEO will be with Cramer this evening.
Missed a big move on ETSY this morning... did reopen too high at 147. Oh well. Asleep at the switch today with another bad tasting nibble.
Closed LVGO (143) and TDOC (223) at profit. Have to figure out just exactly how much since these were added to on dips.
Reopened a smaller position in LVGO and TDOC at 141.80 and 220.95 respectively.
Reopened a nibble of SWT at 106.60, which is considerably higher than my previous close.
SWT:
Stanley Black & Decker: Q3 Earnings Insights
7:10 am ET October 27, 2020 (Benzinga) Print
Shares of Stanley Black & Decker (NYSE:SWK) moved lower by 2% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share increased 35.68% year over year to $2.89, which beat the estimate of $2.68.
Revenue of $3,850,000,000 rose by 5.97% year over year, which missed the estimate of $3,990,000,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Stanley Black & Decker hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Oct 27, 2020
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/ej7zzuyv
Technicals
Company's 52-week high was at $180.94
Company's 52-week low was at $70.00
Price action over last quarter: Up 12.74%
Company Profile
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
I'll take that as one atta boy SF. Thanks.
Oh, and also added to DKNG at 40.
Trimmed CARR at 33.71 from a cost of 24.32- 38.61% return.
Added to AMZN at 3160
And as expected... reopened IBM at 111.95, will add at 107, 105 102.
Trimmed a bit of AAPL at 114 before there's no profit left from a cost basis of 109.86
Good fortune to you as always.
Value ( dividend ) trap ?
And welcome one and all once more to The Spanish Inquisition. !
It was tough SF, but someone had to do it.
Dont underestimate the power of stupid, SF. Good fortune and happy sailing on your odyssey . When you reach landfall, watch out for zombies.
And those that dont take the vaccine ( for whatever conspiratorial, political reasons'll just get sick and die off ).
Dont know about that. SF. But I do know it doesnt have cocaine in it any more (shucks!).
I snorted the contents of a bottle, not a can of coke and... nothing. Just a runny nose.
Oh well....
Cant stay there forever SF.
Correction on AB. Opened in second account at 31.10.
Silly me, I was looking at the wrong number. The days closing number was 31.55
Oops.
INTC has horribly disappointed the last 2 quarters. It went from a good solid reliable money earner to crap. My cost basis is 51.39.
I'll not put another dime into this pos and will gladly and gleefully extricate myself from this quantum mega doggie asap at cost.
And whatever happened to the stimulus. Keeping everyone anxious, not flush with Gov't cash and no high market returns is no fun.
I'll take ho hum any day at this point.
Opened AB in second account at 31.55 and trimmed LVGO and TDOC before all of the profit vanishes.
And fossil fuel is not doing well under this republican president.
The markets steadily went higher with Obama/ Biden. I see no reason for a sell off. Profit taking maybe, but no one that I know is having a stellar year. These markets have been a tough grind. "Normalcy" meaning diminished chaos. That would be nice.
Thanks for the report Nick.
What's your time horizon Nick ?
Too pricey for me right now. Maybe after the ex div.
Opened with a nibble IPO- MCFE at 18.97
As previously stated 112 or below.
107,105, 99 ( doubtful )
The end to oil ! Long live oil !
Good morning !
Added to AAPL at 115.75
Added to DNB at 26.55
Opened CMG at 1305
Added at 1296
Added to RKT 20